Asset
Briquilimab
Jasper Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05903274 | phase1 | terminated | 2023-06-19 | 2024-10-21 | Jasper Therapeutics, Inc. | JSP191 (briquilimab) in Subjects with LR-MDS |
FDA applications (0)
This company has no applications containing this asset.